Medtronic Q3 Earnings: Cardiovascular And Neuroscience Drive Growth, Surgical Revenue Dips, Reaffirms Annual Forecast
1. MDT's Q3 2025 sales fell short of expectations at $8.29 billion. 2. Adjusted EPS of $1.39 exceeded expectations, reflecting strong earnings. 3. Organically, revenue grew 4.1%, signaling solid company performance. 4. Expected revenue growth in FY25 is reaffirmed at 4.75%-5%. 5. MDT stock dropped 5.94% to $87.30 premarket after earnings report.